Lenalidomide
Lenalidomide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hodgkin Lymphoma、B-Cell Lymphoma、Relapsed B-cell NHL、Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- M.D. Anderson Cancer Center
- Canadian Cancer Trials Group
- Janssen Research & Development, LLC
- National Cancer Institute (NCI)
- The First Affiliated Hospital of Xiamen University
- University of Alabama at Birmingham
- Zhejiang Cancer Hospital
- Incyte Biosciences Italy S.r.l
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、意大利、英国、澳大利亚、Georgia、Serbia、Argentina、奥地利、比利时、Brazil、加拿大
正在招募患者的 Lenalidomide 研究
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
I 期招募中美国NCT04301076Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
II 期招募中中国NCT06151080Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
II 期招募中美国NCT04991103RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
II 期招募中中国NCT06674096Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
不适用招募中意大利NCT06299553Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
不适用招募中英国NCT04234022A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
I 期招募中美国澳大利亚中国GeorgiaNCT07477587A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
不适用招募中中国NCT05899621Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
II 期招募中中国NCT07299149A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
III 期招募中美国Argentina澳大利亚奥地利NCT05623020Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
II 期招募中美国NCT05910801Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
II 期招募中西班牙NCT07126236Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
II 期招募中中国NCT07460362Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
I 期 / II 期招募中中国NCT04432714Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
II 期招募中美国NCT06649812Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
II 期招募中美国NCT06461988A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
III 期招募中美国澳大利亚Brazil加拿大NCT06084936An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
不适用招募中意大利NCT06782789Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
II 期招募中西班牙NCT07045909A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
不适用招募中中国NCT06497738A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
不适用招募中South KoreaNCT06698887NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
II 期招募中South KoreaNCT06737250MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
II 期招募中中国NCT06793189Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
早期 I 期招募中美国NCT06142396
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。